These results suggest that doxorubicin chemotherapy may increase the risk of metastasis of drug‐resistant breast cancer cells, and future therapeutics targeting DCAF13 may help reduce the risk, especially for patients undergoing chemotherapy. The gene discussed is DCAF13; the disease is breast cancer.